GLP‑1s are reshaping wardrobes
Retail data now show a tangible wardrobe effect from GLP‑1 weight‑loss drugs: in March, large and extra‑large apparel purchase volume rose 12% year‑over‑year while small and medium resale items fell about 6%, suggesting shoppers and resellers are adjusting sizes and inventory. Companies are responding with services for users too — Choose Health just rolled out at‑home GLP‑1 monitoring panels for Ozempic, Wegovy and Mounjaro users to track safety and side effects. ( )
A weight-loss drug is now showing up in a place you can count on a cash register: clothing sizes. CNBC reported that March 2026 purchase volume for large, extra large and plus-size apparel combined rose 6% from a year earlier, even as small and medium resale items declined, giving retailers one of the first measurable “wardrobe effects” from glucagon-like peptide-1 drugs. (cnbc.com) Those drugs work by mimicking a gut hormone that helps people feel full sooner and eat less, which is why medicines like Wegovy, Ozempic, and Mounjaro have become central to weight-loss treatment. Wegovy’s prescribing information lists nausea, diarrhea, vomiting, and constipation among the most common side effects, which is part of why people often change dose slowly and monitor how they respond. (wegovy.com) The retail change is not just theoretical anymore. CNBC said Stitch Fix has already seen more customers mention weight loss when shopping for new outfits, and Bernstein estimates glucagon-like peptide-1 drugs could add as much as $13 billion a year to apparel spending. (cnbc.com) Stitch Fix is positioned for that shift because its business is built around people telling stylists when their bodies and preferences change. The company reported $341.3 million in second-quarter fiscal 2026 revenue, up 9.4% from a year earlier, while chief executive Matt Baer said its assortment and personalization tools are driving stronger engagement. (investors.stitchfix.com) The timing lines up with a bigger expansion in the drug market itself. CNBC reported that Novo Nordisk launched its Wegovy pill in January 2026 and that more than 600,000 prescriptions had been written by February, while Eli Lilly began shipping its oral glucagon-like peptide-1 drug Foundayo this week through its direct-to-consumer platform. (cnbc.com) More people taking the drugs means more people dealing with the unglamorous part too: lab work and side effects. Choose Health said on April 9 that it launched at-home monitoring panels for Ozempic, Wegovy, and Mounjaro users, with a basic panel covering 8 biomarkers and a comprehensive panel covering 18 biomarkers tied to liver, kidney, and metabolic health. (prnewswire.com) The company’s pitch is convenience. Users order online, do a finger-prick blood sample at home, mail it to a Clinical Laboratory Improvement Amendments-certified lab, and get physician-reviewed results in an online dashboard, according to the launch announcement. (prnewswire.com) This is happening because glucagon-like peptide-1 use is no longer niche. KFF reported in November 2025 that 12% of U.S. adults said they were currently taking a glucagon-like peptide-1 drug, up from 6% who said they were currently taking one in KFF’s May 2024 poll. (kff.org; kff.org) So the story is no longer just about drugmakers selling injections and pills. It is about secondhand sellers getting fewer small and medium items, apparel companies planning for customers who are changing sizes midyear, and testing companies building products for people whose medicine cabinet is changing faster than their closet. (cnbc.com; prnewswire.com)
